-
Study aim
-
Evaluation of the therapeutic effect of medical beer on the fever of patients with COVID-19
-
Design
-
Randomized non-blinded clinical trial, with a sample size of 60, Phase 3 Clinical trial
-
Settings and conduct
-
The location of the project is Amin Hospital in Isfahan and the study will be performed as an A Randomized Clinical Trial.
-
Participants/Inclusion and exclusion criteria
-
Inclusion Criteria: Patients aged 18 to 70 years with inpatient clinical criteria (fever ≥ 38% or severe cough or shortness of breath or respiratory rate ≥ 24 per minute or oxygen saturation <93%), positive PCR, lung involvement in the chest CT scan.
It should be noted that some patients are admitted with clinical symptoms and without a positive corona test, but this study will only be performed on those who have a positive test.
Exclusion criteria: previous COVID-19 treatment, allergy and asthma, hypertension, diabetes, pregnancy, Breastfeeding, heart failure, chronic renal failure, receiving chemotherapy, taking corticosteroids, immune system deficiency
-
Intervention groups
-
Intervention group in addition to be received the prescribed medications to treat COVID-19, they will be received 200 cc of medical beer every 4 hours for 5 days. The control group will be received only the prescribed medications according to the protocol of the Ministry of Health to treat COVID-19.
-
Main outcome variables
-
The length of hospital stay, fever, muscular pain, dry cough, shortness of breath, ESR, CRP, blood cell count, Chest X-ray, Chest CT scan